Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - AccuredShares IssuedShares OutstandingShares Outstanding
Ratios

Fulcrum Therapeutics (FULC) Receivables - Net (2020 - 2022)

Fulcrum Therapeutics (FULC) has 3 years of Receivables - Net data on record, last reported at $13000.0 in Q3 2022.

  • On a quarterly basis, Receivables - Net changed N/A to $13000.0 in Q3 2022 year-over-year; TTM through Sep 2022 was $13000.0, a N/A change, with the full-year FY2021 number at $2.5 million, up 124900.0% from a year prior.
  • Receivables - Net reached $13000.0 in Q3 2022 per FULC's latest filing, down from $357000.0 in the prior quarter.
  • Over the last five years, Receivables - Net for FULC hit a ceiling of $2.5 million in Q4 2021 and a floor of $13000.0 in Q3 2022.
  • A 3-year average of $1.2 million and a median of $1.2 million in 2020 define the central range for Receivables - Net.
  • On a YoY basis, Receivables - Net climbed as much as 25.0% in 2021 and fell as far as 25.0% in 2021.
  • Tracing FULC's Receivables - Net over 3 years: stood at $2.0 million in 2020, then increased by 25.0% to $2.5 million in 2021, then crashed by 99.48% to $13000.0 in 2022.
  • Business Quant data shows Receivables - Net for FULC at $13000.0 in Q3 2022, $357000.0 in Q2 2022, and $2.5 million in Q4 2021.